NeuraLight and Kariya Pharmaceuticals announced a partnership to bring NeuraLight's eye-tracking biomarker platform into Kariya's Phase II program for KP405, a brain-penetrant GLP-1 agonist being developed for Parkinson's and Alzheimer's disease. For NeuraLight, the partnership places its platform within the measurement layer of the GLP-1/neurodegeneration thesis, where more precise biomarkers are needed to track whether popular peptide therapies are actually reaching and protecting the brain.